Hubei Jumpcan Pharmaceutical Co., Ltd.
Shanghai Stock ExchangeTotal Valuation
Hubei Jumpcan Pharmaceutical Co., Ltd. carries a market capitalization of 21.49B, placing it among publicly traded companies globally. Its enterprise value stands at 13.79B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 21.49B |
| Enterprise Value | 13.79B |
Share Statistics
Hubei Jumpcan Pharmaceutical Co., Ltd. currently has 921.70M shares outstanding.
| Shares Outstanding | 921.70M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Hubei Jumpcan Pharmaceutical Co., Ltd. trades at a trailing price-to-earnings ratio of 12.60. The price-to-sales ratio is 3.59, and the price-to-book ratio stands at 2.56.
| PE Ratio | 12.60 |
| PS Ratio | 3.59 |
| PB Ratio | 2.56 |
| P/TBV Ratio | 1.85 |
| P/FCF Ratio | 224.65 |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, Hubei Jumpcan Pharmaceutical Co., Ltd. trades at an EV/EBITDA multiple of 7.20 and an EV/FCF ratio of 111.93. The EV/Sales ratio of 2.05 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 7.20 provides insight into valuation relative to core operating earnings.
| EV / Sales | 2.05 |
| EV / EBITDA | 7.20 |
| EV / EBIT | 7.20 |
| EV / FCF | 111.93 |
Financial Position
Hubei Jumpcan Pharmaceutical Co., Ltd. maintains a current ratio of 4.42, meaning it holds 4.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 3.94, indicating elevated leverage, while an interest coverage ratio of 103.86 demonstrates strong ability to service its debt obligations.
| Current Ratio | 4.42 |
| Quick Ratio | 3.70 |
| Debt / Equity | 3.94 |
| Debt / EBITDA | 0.28 |
| Interest Coverage | 103.86 |
Financial Efficiency
Hubei Jumpcan Pharmaceutical Co., Ltd. posts a return on equity of 20.31 and a return on invested capital of 11.21.
| Return on Equity (ROE) | 20.31 |
| Return on Assets (ROA) | 11.04 |
| Return on Invested Capital (ROIC) | 11.21 |
| Return on Capital Employed (ROCE) | 18.58 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 2.91 |
Taxes
Over the trailing twelve months, Hubei Jumpcan Pharmaceutical Co., Ltd. has paid 338.93M in income taxes, reflecting an effective tax rate of 15.00.
| Income Tax | 338.93M |
| Effective Tax Rate | 15.00 |
Stock Price Statistics
Hubei Jumpcan Pharmaceutical Co., Ltd.'s stock has declined approximately -9.71738% over the past 52 weeks. The 50-day moving average sits at 27.08, while the 200-day moving average is 26.51.
| Beta (5Y) | N/A |
| 52-Week Price Change | -9.71738% |
| 50-Day Moving Average | 27.08 |
| 200-Day Moving Average | 26.51 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Hubei Jumpcan Pharmaceutical Co., Ltd. generated 6.73B in revenue and converted that into 1.92B in net income, yielding earnings per share of 2.09. EBITDA reached 1.92B, while operating income came in at 1.92B.
| Revenue | 6.73B |
| Gross Profit | 5.22B |
| Operating Income | 1.92B |
| Pretax Income | 2.26B |
| Net Income | 1.92B |
| EBITDA | 1.92B |
| EBIT | 1.92B |
| Earnings Per Share (EPS) | 2.09 |
Balance Sheet
Hubei Jumpcan Pharmaceutical Co., Ltd. holds 10.93B in cash and equivalents against 533.44M in total debt, resulting in a net debt position of -4.21B. Total book value stands at 9.44B, with working capital of 10.09B providing operational flexibility.
| Cash & Cash Equivalents | 10.93B |
| Total Debt | 533.44M |
| Net Debt | -4.21B |
| Equity (Book Value) | 9.44B |
| Book Value Per Share | 10.29 |
| Working Capital | 10.09B |
Cash Flow
After subtracting -107.52M in capital expenditures, free cash flow totaled -107.52M - equivalent to -0.12 per share.
| Operating Cash Flow | N/A |
| Capital Expenditures | -107.52M |
| Free Cash Flow | -107.52M |
| FCF Per Share | -0.12 |
Margins
Hubei Jumpcan Pharmaceutical Co., Ltd. operates with a gross margin of 77.60, reflecting its pricing power and cost economics. The operating margin of 28.47 and net profit margin of 28.49 provide insight into operational efficiency.
| Gross Margin | 77.60 |
| Operating Margin | 28.47 |
| Pretax Margin | 33.57 |
| Profit Margin | 28.49 |
| EBITDA Margin | 28.47 |
Dividends & Yields
The company's payout ratio of 100.47 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 2.11 |
| Dividend Yield | N/A |
| Payout Ratio | 100.47 |
| Shareholder Yield | 9.73 |
| FCF Yield | 0.45 |
Stock Splits
Hubei Jumpcan Pharmaceutical Co., Ltd.'s most recent stock split took place on May 18, 2010 with a 10:13 split ratio.
| Last Split Date | 5/18/2010 |
| Split Ratio | 10:13 |
Scores
Hubei Jumpcan Pharmaceutical Co., Ltd. posts an Altman Z-Score of 6.94, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 6.94 |